Cargando…
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the da...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933613/ https://www.ncbi.nlm.nih.gov/pubmed/27340254 http://dx.doi.org/10.1177/1753465816652083 |
_version_ | 1783319980084822016 |
---|---|
author | Greillier, Laurent Tomasini, Pascale Barlesi, Fabrice |
author_facet | Greillier, Laurent Tomasini, Pascale Barlesi, Fabrice |
author_sort | Greillier, Laurent |
collection | PubMed |
description | Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the data from clinical trials available to date regarding efficacy and safety of chemotherapy plus bevacizumab. This review then highlights the current remaining questions related to the use of this drug in daily practice and how the patients might be clinically and radiologically selected. Finally, this review explores the future directions for bevacizumab development in nonsquamous non-small cell lung cancer and for a biological selection of patients with research on predictive biomarkers. |
format | Online Article Text |
id | pubmed-5933613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-59336132018-05-09 Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience Greillier, Laurent Tomasini, Pascale Barlesi, Fabrice Ther Adv Respir Dis Reviews Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the data from clinical trials available to date regarding efficacy and safety of chemotherapy plus bevacizumab. This review then highlights the current remaining questions related to the use of this drug in daily practice and how the patients might be clinically and radiologically selected. Finally, this review explores the future directions for bevacizumab development in nonsquamous non-small cell lung cancer and for a biological selection of patients with research on predictive biomarkers. SAGE Publications 2016-06-23 2016-10 /pmc/articles/PMC5933613/ /pubmed/27340254 http://dx.doi.org/10.1177/1753465816652083 Text en © The Author(s), 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Reviews Greillier, Laurent Tomasini, Pascale Barlesi, Fabrice Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience |
title | Bevacizumab in the treatment of nonsquamous non-small cell lung
cancer: clinical trial evidence and experience |
title_full | Bevacizumab in the treatment of nonsquamous non-small cell lung
cancer: clinical trial evidence and experience |
title_fullStr | Bevacizumab in the treatment of nonsquamous non-small cell lung
cancer: clinical trial evidence and experience |
title_full_unstemmed | Bevacizumab in the treatment of nonsquamous non-small cell lung
cancer: clinical trial evidence and experience |
title_short | Bevacizumab in the treatment of nonsquamous non-small cell lung
cancer: clinical trial evidence and experience |
title_sort | bevacizumab in the treatment of nonsquamous non-small cell lung
cancer: clinical trial evidence and experience |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933613/ https://www.ncbi.nlm.nih.gov/pubmed/27340254 http://dx.doi.org/10.1177/1753465816652083 |
work_keys_str_mv | AT greillierlaurent bevacizumabinthetreatmentofnonsquamousnonsmallcelllungcancerclinicaltrialevidenceandexperience AT tomasinipascale bevacizumabinthetreatmentofnonsquamousnonsmallcelllungcancerclinicaltrialevidenceandexperience AT barlesifabrice bevacizumabinthetreatmentofnonsquamousnonsmallcelllungcancerclinicaltrialevidenceandexperience |